CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Vanda Pharmaceuticals Inc. v. Alembic Pharmaceuticals Limited

1:26-cv-00905

Overview

Case Number 1:26-cv-00905
Filing Date 2026-07-24
Status Litigation filed
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:1 Patent Infringement
Jury Demand None

Parties

Defendant

Alembic Pharmaceuticals, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Alembic Pharmaceuticals Limited NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Vanda Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8586610
Methods for the administration of iloperidone
Filed: 2005-09-30
Issued: 2013-11-19
Active (1.0 yrs remaining) +763d PTA
Expires: 2027-11-02

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+763 days) / Cellect Scrutiny β€” Over 763 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Stipulation to EXTEND Time
Entry #12 • 2026-10-09 Document →
Procedural / Extension Motion Pending / Under Review
Stipulation to EXTEND Time
Entry #10 • 2026-09-24 Document →

Docket Entries

(19 total)
Pleading / Complaint

COMPLAINT for Patent Infringement with Jury Demand against Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-5025017) - filed by Vanda Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(oam) (Entered: 07/24/2026)

Entry #1 • 2026-07-24
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) (Entered: 07/24/2026)

Entry #2 • 2026-07-24
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 06/11/2026. Date of Expiration of Patent: 11/02/2027.Thirty Month Stay Deadline: No earlier than 12/11/2028. (oam) (Entered: 07/24/2026)

Entry #3 • 2026-07-24
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,586,610. (oam) (Entered: 07/24/2026)

Entry #4 • 2026-07-24
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent BlackRock Fund Advisors for Vanda Pharmaceuticals Inc. filed by Vanda Pharmaceuticals Inc. (oam) (Entered: 07/24/2026)

Entry #5 • 2026-07-24
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc